LONDON
NextPharma Technologies Holding Ltd announced today that Mitsubishi Pharma Europe (MPE), the European subsidiary of Mitsubishi Tanabe Pharma Corporation, has selected NextPharma as its fully-serviced outsourcing partner for the European launch of BindRen®. NextPharma will provide tailored, primary and secondary packaging solutions within the European territory. BindRen® is already launched in Germany and Austria with other countries expected to quickly follow.
Mr Toshiaki Mikuni, Vice President MPE commented, “This is an important, high-profile launch for Mitsubishi and selecting a partner who could quickly grasp our needs and add value to our goals was essential”. He added, “We needed a partner with a significant European presence and we were also impressed by the packaging solutions available at NextPharma’s state-of-the-art, solids facility in Germany.”
“It’s a great honour and responsibility to partner with MPE on this important project” said Pierre Delavaud, Executive Vice President, Sales & Marketing, NextPharma. “Our respective teams have worked closely these past months to develop a solution and today we can celebrate a successful result.”
-Ends-
Notes to Editors:
About BindRen
BindRen® (generic name: colestilan) is an orally available non-absorbed anion exchange resin for the treatment of hyperphosphataemia in adult patients with Chronic Kidney Disease (CKD) Stage 5 receiving haemodialysis or peritoneal dialysis.
In the clinical studies in Chronic Kidney Disease patients on dialysis, it improved high blood phosphorus concentration by absorbing phosphate in the gastrointestinal tract and excrete it into the faeces. Also observed are LDL cholesterol and HbA1c level reduction thanks to bile acid absorption in the gastrointestinal tract, as well as serum uric acid level reduction. Reported common adverse reactions include nausea, vomiting, and indigestion.
About NextPharma
NextPharma, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry. The company:
- Offers a full range of services from early phase product development, through clinical trial packaging (Phases I through III), to high volume commercial manufacturing. The company is a world leader in pellet technologies and in specialist product manufacturing including hormones, penicillins, and cephalosporins, in addition to providing manufacturing and packaging services for conventional product forms. Additionally, NextPharma offers integrated logistics solutions tailored to meet the needs of the global pharmaceutical industry.
- Operates globally with six product development centres, six manufacturing plants and six temperature controlled storage and distribution sites across Europe (production facilities in France and Germany), supplying customers in North America, Europe and the rest of the world.
- Has 1,000 employees dedicated to serving over 150 customers worldwide. Its customer base includes many of the world’s leading pharmaceutical, specialty pharma and biotech companies.
About Mitsubishi Pharma Europe
Based in London, Mitsubishi Pharma Europe Ltd (MPE) is the European Headquarters of one of Japan’s largest pharmaceutical companies, Mitsubishi Tanabe Pharma Corporation (MTPC). The company is involved in the research and development, manufacture and supply of pharmaceutical products for human use and aims to contribute to the healthier lives of people around the world through the creation of pharmaceuticals.
CONTACT
Alan Dodsworth
Executive Vice President Corporate Development
NextPharma Technologies Holding Limited (www.nextpharma.com)
Tel: +44 (0) 1483 479 120
